← Browse by Condition
Medical Condition

npm1 mutation

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for npm1 mutation sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — npm1 mutation Clinical Trials

How many clinical trials are currently recruiting for npm1 mutation?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for npm1 mutation, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for npm1 mutation?
npm1 mutation research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a npm1 mutation clinical trial?
Eligibility criteria for npm1 mutation trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Kura Oncology, Inc. 2 trials
The First Affiliated Hospital of Soochow University 1 trial
Massachusetts General Hospital 1 trial

Recruiting Clinical Trials

NCT07101497 Phase 2
Recruiting
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Enrollment
60 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06440135 Phase 1
Recruiting
Ziftomenib Maintenance Post Allo-HCT
Enrollment
22 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT05735184 Phase 1
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Enrollment
420 pts
Location
United States
Sponsor
Kura Oncology, Inc.
View Trial →
NCT06001788 Phase 1
Recruiting
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment
171 pts
Location
United States, Italy...
Sponsor
Kura Oncology, Inc.
View Trial →

Related Conditions

acute myeloid leukemia (3) acute leukemia (2) kmt2a rearrangement (2) aml with mutated npm1 (2) kmt2ar (2) menin inhibitors (1) post hematopoietic stem cell transplantation (1) maintenance therapy (1) nup98 gene rearrangement (1) acute myeloid leukemia in remission (1) mixed lineage leukemia gene mutation (1) refractory aml (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology